[go: up one dir, main page]

WO2012169785A3 - Symmetrically structured quinazoline derivatives - Google Patents

Symmetrically structured quinazoline derivatives Download PDF

Info

Publication number
WO2012169785A3
WO2012169785A3 PCT/KR2012/004475 KR2012004475W WO2012169785A3 WO 2012169785 A3 WO2012169785 A3 WO 2012169785A3 KR 2012004475 W KR2012004475 W KR 2012004475W WO 2012169785 A3 WO2012169785 A3 WO 2012169785A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinazoline derivatives
symmetrically structured
structured
symmetrically
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/004475
Other languages
French (fr)
Other versions
WO2012169785A9 (en
WO2012169785A2 (en
Inventor
In Hwan Bae
Ji Young Song
Eun Young Byun
Wha Il Choi
Ho Seok Kim
Seung Ah JUN
Young Gil Ahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of WO2012169785A2 publication Critical patent/WO2012169785A2/en
Publication of WO2012169785A3 publication Critical patent/WO2012169785A3/en
Publication of WO2012169785A9 publication Critical patent/WO2012169785A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel quinazoline derivative and a pharmaceutical composition for preventing or treating cancers, inflammatory diseases, autoimmune diseases, or neurodegenerative disorders comprising same as an active ingredient.
PCT/KR2012/004475 2011-06-07 2012-06-07 Symmetrically structured quinazoline derivatives Ceased WO2012169785A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110054581A KR20120135716A (en) 2011-06-07 2011-06-07 Symmetrically structured quinazoline derivative compounds and use thereof
KR10-2011-0054581 2011-06-07

Publications (3)

Publication Number Publication Date
WO2012169785A2 WO2012169785A2 (en) 2012-12-13
WO2012169785A3 true WO2012169785A3 (en) 2013-03-28
WO2012169785A9 WO2012169785A9 (en) 2013-05-23

Family

ID=47296590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004475 Ceased WO2012169785A2 (en) 2011-06-07 2012-06-07 Symmetrically structured quinazoline derivatives

Country Status (2)

Country Link
KR (1) KR20120135716A (en)
WO (1) WO2012169785A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061283B (en) * 2015-08-09 2017-11-24 浙江大学 The preparation method of amino-acid benzyl ester hydrochloride
WO2019023275A1 (en) * 2017-07-25 2019-01-31 Hepagene Therapeutics, Inc. Dimeric peptide inhibitors of apoptosis proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
US20080027084A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Modulators of chemokine receptor activity crystalline forms and process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
US20080027084A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Modulators of chemokine receptor activity crystalline forms and process

Also Published As

Publication number Publication date
WO2012169785A9 (en) 2013-05-23
WO2012169785A2 (en) 2012-12-13
KR20120135716A (en) 2012-12-17

Similar Documents

Publication Publication Date Title
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
HK1207069A1 (en) Heterocyclic compounds and uses thereof
HK1212609A1 (en) Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
LT3470063T (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR-RELATED DISEASES
HK1199725A1 (en) Heterocyclic compounds and uses thereof
HK1198443A1 (en) Heterocyclic compounds and uses thereof
HK1219483A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2012174158A3 (en) Administration of benzodiazepine
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2013134047A3 (en) Aminoquinoline derivatives and uses thereof
WO2015077503A8 (en) Autotaxin inhibitor compounds
HK1218621A1 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
HK1206726A1 (en) Imidazotriazinone compounds
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
HK1213779A1 (en) Composition for immediate and extended release
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2014100735A3 (en) Diazole amides
MX363530B (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof.
WO2013100718A3 (en) Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
WO2014145126A3 (en) Methods of treating dyskinesia and related disorders
WO2015082590A3 (en) Bis-mmf derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12796519

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12796519

Country of ref document: EP

Kind code of ref document: A2